DIABETICMedicine

DOI: 10.1111/j.1464-5491.2009.02866.x

Review Article
Peripheral arterial disease in diabetes—a review

E. B. Jude, I. Eleftheriadou* and N. Tentolouris*

Tameside General Hospital, Ashton-Under-Lyne, UK and *Athens University Medical School, Athens, Greece

Accepted 23 September 2009

Abstract
Diabetic patients are at high risk for peripheral arterial disease (PAD) characterized by symptoms of intermittent
claudication or critical limb ischaemia. Given the inconsistencies of clinical findings in the diagnosis of PAD in the
diabetic patient, measurement of ankle-brachial pressure index (ABI) has emerged as the relatively simple, non-invasive
and inexpensive diagnostic tool of choice. An ABI < 0.9 is not only diagnostic of PAD even in the asymptomatic patient,
but is also an independent marker of increased morbidity and mortality from cardiovascular diseases. With better
understanding of the process of atherosclerosis, avenues for treatment have increased. Modification of lifestyle and
effective management of the established risk factors such as smoking, dyslipidaemia, hyperglycaemia and hypertension
retard the progression of the disease and reduce cardiovascular events in these patients. Newer risk factors such as
insulin resistance, hyperfibrinogenaemia, hyperhomocysteinaemia and low-grade inflammation have been identified,
but the advantages of modifying them in patients with PAD are yet to be proven. Therapeutic angiogenesis, on the
other hand, represents a promising therapeutic adjunct in the management of PAD in these patients. Outcomes after
revascularization procedures, such as percutaneous transluminal angioplasty and surgical bypasses in diabetic
patients, are poorer, with increased perioperative morbidity and mortality compared with that in non-diabetic
patients. Amputation rates are higher due to the distal nature of the disease. Efforts towards increasing
awareness and intensive treatment of the risk factors will help to reduce morbidity and mortality in diabetic patients
with PAD.
Diabet. Med. 27, 4–14 (2010)
Keywords ankle-brachial pressure index, diabetes, peripheral arterial disease, risk factors, treatment

Abbreviations ABI, ankle-brachial pressure index; bFGF, basic fibroblast growth factor; cAMP, cyclic adenosine-3¢,5¢-
monophosphate; CRP, C-reactive protein; DM, diabetes mellitus; HGF, hepatocyte growth factor; HTN, hypertension;
LDL, low-density lipoprotein; MI, myocardial infarction; NGF, nerve growth factor; NO, nitric oxide; PAD, peripheral
arterial disease; PAI, plasminogen activator inhibitor; PCTA, percutaneous transluminal balloon angioplasty; SBP,
systolic blood pressure; T1DM, Type 1 diabetes mellitus; T2DM, Type 2 diabetes mellitus; TcPO2, transcutaneous
partial pressure of oxygen; UKPDS, United Kingdom Prospective Diabetes Study; VEGF, vascular endothelial growth
factor; vWF, von Willebrand factor

ischaemic ulceration or gangrene. Diabetic patients with PAD are

Introduction
Peripheral arterial disease (PAD) is a group of disorders
characterized by narrowing or occlusion of the arteries
resulting in gradual reduction of blood supply to the limbs.
Patients with PAD may be asymptomatic or may develop
symptoms of intermittent claudication or symptoms of critical
limb ischaemia, characterized by pain in the peripheries at rest,
Correspondence to: Edward B. Jude, MD, Tameside General
Hospital, Ashton-Under-Lyne, Lancashire OL6 9RW, UK.
E-mail: edward.jude@tgh.nhs.uk
at high risk of increased morbidity and mortality from
cardiovascular diseases. Considering that between 120 and
140 million people suffer from diabetes mellitus (DM)
worldwide and that diabetic patients are at excess risk of
developing PAD [1], the implications of the problem are
enormous.
The importance of PAD in DM is several-fold. PAD may be
asymptomatic until it reaches an advanced stage [2]. It presents at
an earlier age and progresses more rapidly than in non-diabetic
patients. It is usually more severe in extent [3] and often not all
patients may be offered a revascularization procedure when

ª 2010 The Authors.

4 Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
 Review article DIABETICMedicine

needed. Furthermore, the outcome after revascularization

procedures is poorer and many patients progress to a major

2 ⁄ 1000 at 30 years of age

6 ⁄ 1000 at 60 years of age
7 ⁄ 1000 at 70 years of age
amputation [3]. The presence of PAD is in itself an independent

17.6 ⁄ 1000 for women

8.4 ⁄ 1000 for women

21.3 ⁄ 1000 for men

12.6 ⁄ 1000 for men

factor for increased mortality due to associated cardiovascular
and cerebrovascular diseases [1]. Finally, early detection of PAD
helps in risk factor modification, which reduces progression and

Incidence

13 ⁄ 1000
improves outcome.

NA
NA
NA
NA
NA
Epidemiology

20% in age ‡ 75 years

3% in age < 60 years
The true incidence of PAD is difficult to ascertain and
estimates can be erroneous due to several reasons. A
significant number of patients with PAD are unlikely to

Prevalence
complain of intermittent claudication because the presence of
peripheral neuropathy may mask the symptoms of claudication

17.3%
38.0%
23.5%

33.0%
8.0%

8.7%

NA

NA
[2]. Furthermore, the method used to diagnose PAD
[symptoms of claudication, palpation of peripheral pulses or
ankle-brachial pressure index (ABI)] has a major influence on

Number of
statistics. The results of various clinical trials [4–11] on the

patients

1073

1084

5209
48
173

864
213

642

586
prevalence and incidence of PAD in DM are summarized in
Table 1.

extremity amputation
IC, foot ulcer, lower
Diagnostic criterion

non-invasive testing
Prevalence

IC or pulse deficit

IC, pulse deficit,

Large population-based studies have shown that the prevalence
Pulse deficit

ABI < 0.9

ABI < 0.9

ABI < 0.9
ABI < 0.9
of PAD is higher in patients with DM. The Framingham study [4]
showed that there was a 3.5- and 8.6-fold excess risk among men

IC
and women, respectively, of developing PAD in patients with
Table 1 Epidemiological data for peripheral arterial disease in patients with and without diabetes mellitus

DM. In the Rochester study the prevalence of PAD at the time of

Type 1 and Type 2 diabetes mellitus

Type 1 and Type 2 diabetes mellitus

Type 1 and Type 2 diabetes mellitus

Type 1 and Type 2 diabetes mellitus

diagnosis of DM was 8% between the years 1945 and 1969,
while it was 10.5% in 1970 [5]. The Hoorn study found that the

ABI, ankle-brachial pressure index; IC, intermittent claudication; NA, not available.
prevalence of ABI < 0.9 in individuals with normal glucose

(26% with diabetes mellitus)

tolerance was 7% and increased to 20.9% in diabetic patients
Type 2 diabetes mellitus
Type 1 diabetes mellitus

Type 1 diabetes mellitus

[6], while a pilot study found a prevalence of asymptomatic PAD
General population

General population
of 33% [7].
One study showed that the type of DM does not affect the
Population

prevalence of PAD, identical prevalences being found in

patients with Type 1 (T1DM) and Type 2 DM (T2DM) [8].
However, another study found a much higher prevalence of
PAD (23.5%) in patients with T2DM than in those with
T1DM (8.7%) [9].
1995
1984
1992
1992
1999
1985

1985

2002
1945–1969
Years

Incidence

In the Rochester study [5], the cumulative incidence of PAD in

USA, Minnesota

DM was 21.3 ⁄ 1000 person-years for men and 17.6 ⁄ 1000

North America
Hoorn study

Framingham

person-years for women. In this study, the cumulative

Australia

incidence of PAD was 15% 10 years after the diagnosis of

Country

DM, which increased to 45% 20 years later. In the Framingham

UK
UK
UK

UK

study [4] the incidence of PAD in the diabetic population was

12.6 ⁄ 1000 person-years for men and 8.4 ⁄ 1000 person-years for
References

women, while the figures in non-diabetic people were 3.3 and

1.1 ⁄ 1000 person-years for men and women, respectively.
10

11
5

6
8
9
9
7

One single study examined the incidence of PAD in patients

4

with T1DM [11]; the incidence was 13 events ⁄ 1000 person-

ª 2010 The Authors.

Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14 5
DIABETICMedicine
years with no gender difference and was similar to that in patients
with T2DM.
Amputation rate
Diabetic patients have increased risk of lower-extremity
amputations in comparison with non-diabetic subjects and
there is no convincing evidence that revascularization
procedures are effective in preventing amputation [3].
Moreover, the severity of PAD in DM assessed
angiographically has been associated with major amputations
[12].
Mortality
Large population-based studies have shown that diabetic
patients with PAD have a three- to four-fold increased
mortality compared with healthy individuals [6], and patients
with critical limb ischaemia and DM have a shorter amputation-
free survival period than patients with critical ischaemia but
without DM [13]. The 5-year mortality in diabetic patients with
critical limb ischaemia is 30% [14].
Risk factors for PAD in diabetes
Various risk factors have been described for the increased
predisposition to the development of PAD in DM. Many studies
[4,5,9–11,15–27] have attempted to resolve this complicated
issue by comparing diabetic patients with PAD with non-diabetic
patients with PAD and between diabetic patients with and
without PAD.
Increasing age correlates strongly with PAD in patients with
both T1DM and T2DM [9]. Although in the Framingham study
[4] much of the excess risk associated with DM was found in
those < 75 years old, the Framingham-offspring study found that
for each 10 years of age, the odds ratio of PAD was 2.6 [15].
In the Framingham and Rochester studies, the incidence of
PAD was higher in men than in women [4,5]. Diabetic women
are more likely to have PAD compared with non-diabetic women
of similar age [16]. While premenopausal women in the general
population enjoy relative protection from atherosclerosis due to
their hormonal status, DM blunts the benefit of the female gender
[10], especially in the elderly group.
In the United Kingdom Prospective Diabetes Study (UKPDS)
[17], duration and degree of hyperglycaemia were associated
with an increased risk for incident PAD independently of other
factors. Each 1% increase in HbA1c was associated with a 28%
excess risk for incident PAD at the end of 18 years. In another
study, the odds ratio of PAD was 28.9 and 51.1 for a DM
duration of 20–29 years and > 30 years, respectively, in patients
with T1DM, while it was 3.8 and 4.3 for a DM duration of 10–
19 years and > 20 years, respectively, in patients with T2DM
[18].
The UKPDS found that increased systolic blood pressure (SBP)
was an independent risk factor for PAD and each 10-mmHg
6 Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
Peripheral arterial disease in diabetes • E. B. Jude et al.
increase in SBP was associated with a 25% increased risk for
development of PAD at the end of 18 years [17]. Tight BP control
was also associated with lower prevalence of PAD at long-term
follow-up in the UKPDS [19]. Other factors have also been
associated independently with PAD in patients with both T1DM
and T2DM. These are summarized in Table 2.
Pathogenesis of PAD in diabetes
Vascular disease in DM affects both the microcirculation and
large vessels. Microangiopathy is characterized by involvement
of blood vessels at the level of the arterioles and capillaries,
causing thickening of the basement membrane and making it
more permeable to plasma solutes. PAD in diabetic patients is
due to the angiopathy affecting the medium-sized arteries
predominantly and is due to the abnormal metabolic state that
prevails in DM. The most important metabolic aberrations are
chronic hyperglycaemia, insulin resistance and dyslipidaemia,
which render the arteries susceptible to atherosclerosis. Various
types of affected cells work in tandem to create atheroma, the
hallmark of atherosclerosis. In brief, some of the cellular events in
the process of atherosclerosis are as follows.
DM impairs endothelial function, through hyperglycaemia,
excess circulating free fatty acids, increased oxidative stress and
inhibition of endothelial nitric oxide (MO) synthase. Thus, there is
a decrease in NO and prostacyclin and an increase in endothelin-I
and angiotensin-II, which are potent vasoconstrictors [28].
DM augments the process of atheroma formation. There is an
increase in plasma and cellular concentration of histamine, which
may contribute to the increased endothelial permeability in
diabetic patients with PAD [28]. The migration of T lymphocytes
into the intima, their activation and secretion of cytokines is
enhanced. Monocytes ingest oxidized low-density lipoprotein
(LDL) molecules on reaching the subendothelial space and
become foam cells, which lead to fatty streak formation, the
precursors of the atheroma. The atheromatous plaque so formed
is unstable as diabetic endothelial cells secrete cytokines that
inhibit production of collagen by smooth muscle cells [29]. They
also secrete metalloproteinases, which break down the collagen
in the fibrous cap of atheromas, leading to a tendency to plaque
rupture and thrombus formation [30]. Endothelial cells produce
increased amounts of tissue factor, a major procoagulant factor.
Migration of medial vascular smooth muscle cells into the intimal
fatty streak lesion is enhanced. These cells then produce
extracellular matrix, aggravating atheroma formation.
Hyperglycaemia also increases intracellular concentration of
glucose in platelets as its uptake is non-insulin dependent. This
leads to decreased production of platelet-derived NO and excess
production of oxygen free radicals [29].
Calcium haemostasis regulating platelet shape, secretion,
aggregation and thromboxane production is disturbed in DM
[31]. Platelet expression of receptor proteins for von Willebrand
factor (vWF) and fibrin products is increased in DM, which could
be the result of decreased production of the antiaggregants NO
and prostacyclin, and increased production of fibrinogen and
ª 2010 The Authors.
 Review article DIABETICMedicine

Table 2 Risk factors for peripheral arterial disease in diabetes mellitus

References Risk factor Type of diabetes mellitus

1,4,5,9,15,17,28 Increasing age 1, 2

4,5,10 Male gender 2
1,5,11,17,18,21,28 Duration of diabetes mellitus 1, 2
17,28 Degree of hyperglycaemia 2
4,15,17 Smoking 2
4,11,15,17,19 Hypertension 1, 2
9,11,15,17,18,20,21 Dyslipidaemia 1, 2
22 Increased serum lipoprotein (a) levels 1, 2
23 Reduced serum apolipoprotein (a) levels 2
9,15,21 Obesity, central body fat distribution 2
11,24 Insulin resistance 1, 2
1,15 Increased serum fibrinogen levels 2
25 Hyperhomocysteinaemia Non-diabetics
9,11,18 Microalbuminuria 1, 2
26 Increased levels of von Willebrand factor 2
26 Increased levels of thrombin–antithrombin complexes 2
27 Increased levels of intercellular adhesion molecules 2

platelet activators such as thrombin and vWF [32]. This increase
in intrinsic platelet activity contributes to the state of enhanced
thrombotic potential.
Diabetic patients have impaired fibrinolytic activity [1]. In
addition, there are increased circulating levels of procoagulants
such as tissue factor, factor VII and decreased levels of
anticoagulants such as antithrombin-III and protein C, thus
favouring a tendency to coagulation, impaired fibrinolysis and
persistence of thrombi [33].
Patients with impaired glucose tolerance have elevated levels of
C-reactive protein (CRP), which is strongly associated with PAD.
CRP inhibits endothelial NO synthase and stimulates the
production of procoagulant tissue factor, leucocyte adhesion
molecules, chemotactic substances and plasminogen activator
inhibitor (PAI)-1 and thus contributes to a thrombotic
environment [28].
Profile of PAD in diabetes
The pattern of PAD involvement differs between diabetic and
non-diabetic patients. Diabetic patients with PAD commonly
show involvement of the arteries below the knee, especially at
the tibial and peroneal arteries, and involvement of the
profunda femoris [3]. Also, it is more commonly symmetrical
and multi-segmental, and stenoses can be seen even in the
collateral vessels. Non-diabetic patients with PAD usually
present with single, unilateral, proximal arterial involvement.
Some, but not all studies, reported that PAD progresses more
rapidly in DM.
Clinical presentation
The majority of diabetic patients with PAD are asymptomatic
(up to 75%) when ABI < 0.9 is the criterion for the diagnosis. The
PARTNERS programme [34] showed that 48% of the 6369
patients, of whom 41% had DM, were aware of their condition.
Some data suggest that patients with DM develop more
symptomatic forms of PAD such as intermittent claudication,
foot ulcers and critical limb ischaemia symptoms [35], while
other studies have found no difference in the frequency of
symptoms between diabetic and non-diabetic patients [9].
Diabetic patients with decreased pain perception due to
peripheral neuropathy may delay the recognition of PAD [2].
Peripheral neuropathy and PAD are known risk factors for
foot ulceration [36]; almost 40–60% of diabetic patients with
foot ulcers have PAD, which is associated with a higher
amputation rate and mortality [36]. With impaired circulation
and sensation, foot ulceration and infection develop commonly.
Development of dry gangrene is the end-stage presentation of
PAD, indicating that in the absence of a revascularization
procedure a major amputation is unavoidable.
Diabetic patients with PAD have poorer lower extremity
function compared with non-diabetic subjects with PAD; they
have shorter mean walking distance and slower fast pace
velocities than non-diabetic patients with PAD. This was due
to the associated peripheral neuropathy, differences in exertional
leg symptoms and greater cardiovascular disease in diabetic
patients [37].
Diagnosis of PAD
A history of intermittent claudication or absence of peripheral
pulses on palpation is unreliable for detection of PAD. The
dorsalis pedis pulse is absent congenitally in about 10–15% of the
population. However, a history of claudication, presence of
bruits proximally and findings of chronic ischaemia in the
peripheries such as cold feet, pallor on limb elevation and
dependent rubor, trophic skin changes and distal gangrene are all

ª 2010 The Authors.

Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14 7
DIABETICMedicine
diagnostic of PAD. Peripheral Doppler ultrasonography, colour
duplex scanning, ABI measurement, plethysmography,
transcutaneous oximetry [transcutaneous partial pressure of
oxygen (TcPO2)] and magnetic resonance angiography are the
battery of non-invasive tests currently available.
An ABI < 0.9 has been used as a criterion for diagnosis in most
studies on PAD, because of its simplicity and non-invasiveness
(Table 3). However, studies on resting ABI and post-exercise ABI
have been conflicting. An arteriographically controlled study
showed that significant stenoses (> 50%) were present in diabetic
patients with palpable foot pulses and ABI > 1 [12]. Questions
have been raised about the reliability of ABI in the diagnosis of
PAD as it was found that ABI was high in hypotensive or
normotensive patients and low in hypertensive patients [38]. The
sensitivity and specificity of ABI were 70.6% and 88.5%,
respectively, in patients with PAD diagnosed by colour duplex
ultrasound [1].
Measurement of pre- and post-exercise ABI is currently
recommended for the screening and diagnosis of PAD, until
more reliable diagnostic tools become available. The ABI
measured with ankle SBP just before and after 5 min of
exercise may reveal significant PAD before resting ABI
becomes abnormal. A drop in ankle BP > 20% indicates
significant PAD, while an absence of such a fall virtually rules
out PAD [1]. Medial arterial calcification (Mönckeberg’s
sclerosis), found in up to 47% of patients with T1DM in one
study [39], is common in patients with DM or renal failure and in
heavy smokers and this can falsely raise ABI to values > 1.3 [1],
masking the presence of PAD [40]. A recent study suggested that
diabetic patients with an ABI ‡ 1.4 should be considered as
PAD-equivalent [40]. Medial arterial calcification may also
render the artery non-compressible and hence ankle BP may not
be assessable. However, the presence of calcification is not a
measure of the severity of the disease or the extent of
stenosis ⁄ occlusion. An alternative approach in these patients is
to measure the great toe BP using a strain gauge sensor or a
photoplethysmograph [2]. Determination of TcPO2 may help
assess healing of ischaemic skin lesions, but is not reliable for the
diagnosis of PAD in DM [2]. Continuous-wave Doppler may
identify occlusive PAD but is a qualitative test only. Colour
Table 3 The role of ankle-brachial pressure index (ABI) for the diagnosis of peripheral arterial disease (PAD) in patients with diabetes mellitus
Advantages References
Simple 1,28
Non-invasive 1,28
Reproducible 1,28
Sensitivity of 90% and specificity 98% 1,28
for the detection of haemodynamically
significant (> 50%) stenosis in leg arteries
Post-exercise ABI: drop of ankle-blood 1
pressure > 20% indicates PAD
8 Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
Peripheral arterial disease in diabetes • E. B. Jude et al.
duplex ultrasound and magnetic resonance angiography help in
localizing PAD lesions and planning intervention. Traditional or
digital subtraction angiography remains the gold standard
against which all other diagnostic modalities should be
compared. It is to be used when a vascular intervention is
planned [1]. A proposed protocol for the diagnosis of PAD in
patients with and without DM is depicted in Fig. 1.
Treatment
The aims in the management of the diabetic patient with PAD are
to improve symptoms and to prevent cardiovascular morbidity
and mortality. Treatment of PAD can be considered in three
stages: lifestyle and risk factor modifications, drug therapy and
vascular interventions.
Lifestyle modifications
Lifestyle modifications are the first mode of therapy as metabolic
and lipid abnormalities improve with smoking cessation,
exercise, weight loss and dietary modifications.
Cigarette smoking is the single most important risk factor for
the development of atherosclerosis and smoking cessation may
halt the progression of disease [28]. Smoking increases the risk
and reduces the success of peripheral vascular intervention [15].
Physical exercise improves exercise tolerance and most of the
studies have shown at least a doubling in walking distance [41].
Noteworthy, these changes were found without significant
improvement in blood flow, but exercise increases
cardiovascular fitness, oxidative enzyme activities, NO
production and insulin sensitivity [29], enhances utilization of
fatty acids in calf muscles, and improves walking biomechanics
as well as blood rheology. Exercise training leads to modest
reductions in BP, cholesterol and glucose levels.
Risk factor modifications
Glycaemic control
There is no conclusive evidence to suggest that optimal glycaemic
control lowers the risk of PAD [42]. In the presence of an
Disadvantages References
ABI ‡ 1.4 (medial arterial calcification) unreliable, 28,40
should be considered as PAD equivalent
Arteriographically evident stenoses > 50% 12
with resting ABI > 1
› ABI in hypotensive or normotensive patients 38
fl ABI in hypertensive patients
ª 2010 The Authors.
 Review article
FIGURE 1 Proposed protocol for the diagnosis of peripheral arterial disease (PAD) in patients with and without diabetes mellitus. Reprinted with
permission from N Engl J Med 2001; 344: 1608–1621. ABI, ankle-brachial index; TBI, toe-brachial index.
increased risk of cardiovascular events with increasing levels of
glycaemia [17] and hyperglycaemia being the important
metabolic factor in atherogenesis, optimal glycaemic control
would be sensible in patients with PAD. Medications that
improve insulin resistance may have advantages over other
hypoglycaemic agents, since insulin resistance is a risk factor for
PAD. However, metformin was not superior to sulphonylureas
or insulin in the prevention of PAD in DM [42]. In the
PROACTIVE study only patients without PAD at baseline
benefited from treatment with pioglitazone [43].
Dyslipidaemia
Aggressive management of dyslipidaemia in patients with DM
and PAD is warranted and the primary aim is LDL-cholesterol
levels < 2.6 mmol ⁄ l or even lower (< 1.8 mmol ⁄ l) [28]. Statins
are the treatment of choice in such patients. The 4S-Study [44]
showed that simvastatin reduced claudication in patients with
PAD, although there were no specific data regarding diabetic
patients. The Heart Protection Study showed that lowering LDL-
cholesterol with simvastatin reduces cardiovascular mortality
and morbidity in diabetic patients by almost 25% [45], while the
Collaborative Atorvastatin Diabetes Study showed that
aggressive treatment with atorvastatin in diabetic patients
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
DIABETICMedicine
reduced major cardiovascular events by 37%, irrespective of
pretreatment LDL-cholesterol levels [46].
Hypertension
Optimal control of hypertension (HTN) to 130 ⁄ 80 mmHg
reduces stroke and death rates. Long-term tight BP control was
associated with a 50% lower risk for PAD in the UKPDS with no
difference between the primary medications (captopril and
atenolol) used for the management of HTN [19]. The HOPE
study [47] showed that ramipril decreased the rates of
myocardial infarction (MI), stroke and death in diabetic
patients with cardiovascular disease. The reduction of
cardiovascular morbidity and mortality in patients with PAD
was 25%. A recent study also showed that intensive BP control
reduces the risk for cardiovascular events in diabetic patients
with PAD [48].
There have been no reports of worsening of symptoms after
control of HTN in patients with PAD. A meta-analysis concluded
that b-blockade was not associated with reduced treadmill
walking performance in PAD patients with intermittent
claudication [49]. Currently, it is recommended that b-blockers
be used as and when indicated, except in patients with critical
limb ishaemia.
9
DIABETICMedicine
Drug therapy
Antiplatelet agents
Antiplatelet agents are of benefit in patients with PAD, as platelet
hyperactivity leads to formation of thrombus at sites of
atherosclerotic plaques. Antiplatelet agents produce
angiographic improvement, increase walking distance, reduce
the need for vascular intervention, improve patency rates after
vascular interventions and reduce cardiovascular mortality. The
Anti-platelet Trialists’ Collaboration has shown that an
antiplatelet agent, usually aspirin, reduces cardiovascular
deaths by 25% in patients with symptomatic atherosclerotic
disease. This reduction in death rates was 18% in the subset of
patients with intermittent claudication [50]. However, these
studies have not reported data separately in diabetic patients with
PAD.
Aspirin alone is as effective as aspirin combined with
dipyridamole, sulphinpyrazone or ticlopidine in preventing
graft occlusion or reduction in risk of death from
cardiovascular events [51]. However, aspirin with dipyridamole
resulted in least progression of PAD compared with aspirin alone
or placebo in an arteriographically controlled trial [52]. A dose of
325 mg did not show any additional benefit over a dose of 75 mg.
Ticlopidine, an antiplatelet thienopyridine agent, improves
clinical outcomes in patients with PAD but is not recommended
because of adverse effects (neutropenia and thrombotic
thrombocytopenic purpura).
Clopidogrel is a second-generation thienopyridine drug with
fewer side-effects. The CAPRIE study [53] compared
clopidogrel with aspirin in > 19 000 patients and found that
the overall decrease in the primary endpoints of MI, stroke or
vascular deaths was 8.7%, and clopidogrel decreased the end-
point of MI by 19.2% over that of aspirin irrespective of the
primary cardiovascular disease. The study also showed that in
the subgroup (about 30% of the 19 000 patients) with PAD at
baseline, those who received clopidogrel had 24% lower
primary end-points of MI, stroke or vascular death in
comparison with aspirin. However, there was no particular
reference to DM.
Intermittent claudication
Two agents are available for the treatment of intermittent
claudication: pentoxifylline and cilostazol. Pentoxifylline, a
methylxanthine derivative is a haemorheological agent that
reduces blood viscosity. It also has antiplatelet action and reduces
serum fibrinogen levels. Results of pentoxifylline in claudication
varied in different studies, with some suggesting favourable
results in diabetic patients but most demonstrating a modest
improvement in symptoms suggesting that pentoxifylline is not
justified for routine use [28]. Pentoxifylline may benefit patients
with severe claudication symptoms and those in whom exercise
and ⁄ or cilostazol is not effective or is contraindicated.
Cilostazol, a quinolone derivative, is a selective
phosphodiesterase-III inhibitor that suppresses cyclic adenosine-
3¢,5¢-monophosphate(cAMP)degradation. Increasedintraplatelet
10
Peripheral arterial disease in diabetes • E. B. Jude et al.
cAMP inhibits thromboxane A2 production and platelet
aggregation by inhibiting phospholipase and cyclooxygenase.
Cilostazol induces vasodilation by inhibiting calcium-induced
contractions of smooth muscle cells.
Treatment with cilostazol increases pain-free and maximal
treadmill walking distances and improves quality of life
significantly more than pentoxifylline [54]. A pooled analysis
of eight Phase III trials of 436 diabetic patients with intermittent
claudication showed that patients who received cilostazol
increased their maximal walking distances, initial claudication
distance and absolute claudication distance more than those with
placebo [55]. Response rates and safety data were similar in
patients with and without DM.
Cilostazol is contraindicated in patients with congestive heart
failure and severe hepatic or renal impairment. Cilostazol is a
promising therapy for patients with claudication and DM among
the limited options available for these patients [2].
The above drugs for intermittent claudication are
recommended in the event of failure of lifestyle modifications.
Clinical trials have shown no efficacy of vasodilator drugs such as
papavarine in PAD and they are not recommended.
Drugs of possible benefit
Iloprost, a prostacyclin derivative, reduces levels of PAI-1 (which
is associated with increased fibrinogen levels and
hypercoaguability) and also increases walking capacity in
diabetic patients with PAD [56]. Further studies are required
before iloprost could be recommended for use.
Critical leg ischaemia
In patients with critical leg ischaemia a revascularization
procedure should always be considered. In addition,
appropriate foot care, sufficient footwear, debridement of foot
ulcers, non-adherent dressings and treatment of infections with
antibiotics are essential for preventing amputation [1].
Therapeutic angiogenesis
Therapeutic angiogenesis represents a novel approach to increase
blood flow to ischaemic tissues by induction of a collateral
vascular network. This can be achieved by administration of
angiogenic factors such as vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), hepatocyte
growth factor (HGF) and nerve growth factor (NGF). Two
modes of angiogenesis are emerging; the first is the topical (into
the muscles or arteries of the lower limbs) administration of the
recombinant growth factor protein, and the second is
incorporation of genes encoding angiogenic growth factors into
a vector (virus or plasmid) to deliver DNA to human cells [57].
Topical, rather than intravenous, administration of these factors
is preferred because systemic toxicity is low and higher
concentrations of the growth factors are achieved locally.
Intramuscular administration of VEGF and intra-arterial
administration of bFGF resulted in clinical improvement.
Importantly, both treatments were safe and well tolerated [57].
Treatment with bFGF gene therapy by intramuscular injection
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
 Review article DIABETICMedicine

FIGURE 2 Proposed protocol for the management of peripheral arterial disease (PAD) in patients with diabetes mellitus (DM). AE, adverse effects; VEGF,
vascular endothelial growth factor; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; NGF, nerve growth factor; PCTA, percutaneous
transluminal balloon angioplasty; BG, bypass grafting.

into thigh and calf muscles in patients with severe limb ischaemia
resulted in improvement in clinical outcomes [57]. However,
only a few patients with DM were included in these studies and
we must wait to gain confidence in the efficacy of these treatments
in patients with DM. HGF and NGF promote neovascularization
in experimental DM [57] and experience in humans is limited.
Human bone-marrow cells contain stem cells that have the
potential for differentiation into a variety of tissues, including
endothelium. Transplantation of autologous bone-marrow stem
cells in 10 patients with severe PAD into the common femoral
artery and the thigh and calf muscles resulted in clinical
improvement and increase in ABI. In another study, autologous
peripheral blood stem cells in 62 patients with severe PAD were
transplanted into the lower limb muscles. All indices of blood
flow improved, while pain was reduced in 87% of the patients
[58]. Although clinical experience is limited, stem cell therapy
represents a promising therapeutic adjunct in the management of
PAD and further research is needed.
It is early to conclude on the position of the novel therapies in
the management of PAD in DM and more data from randomized
controlled trials are necessary to establish their efficacy and
safety. However, given that the tibial arteries are predominantly
involved in diabetes, and that revascularization procedures are
not usually performed at this site, their indication may be for the
management of severe limb ischaemia not amenable to
revascularization surgery. They may also be useful for the

ª 2010 The Authors.

Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14 11
DIABETICMedicine
management of PAD in patients at high surgical risk due to severe
comorbidities.
Revascularization procedures
Classically, the indications for a revascularization procedure in
PAD are disabling claudication affecting quality of life after
medical therapy has failed to improve symptoms, and critical
limb ischaemia symptoms. The revascularization procedures
currently available are percutaneous transluminal balloon
angioplasty (PCTA) with or without stenting and surgical
revascularization by means of bypass grafting using
autogenous vein or a synthetic graft or endarterectomy for
localized lesions.
The number of revascularization procedures for PAD is about
8- to16-fold higher in diabetic compared with non-diabetic
patients. Additionally, patients with DM have distal
revascularization procedures more often than non-diabetic
patients [1]. The choice of a procedure depends on many
factors such as site and extent of the disease, distal run off and
surgical risk due to associated cardiovascular disease. Proximal,
short segment disease in the iliac and femoral segments is
amenable to PCTA, with results comparable to that in non-
diabetic patients. More distal disease in the popliteal and tibial
arteries is better managed by bypass grafting, but with a higher
peri-procedural morbidity and mortality [1]. PCTA below the
knee is restricted to patients with critical limb ischaemia who are
at high risk during surgical revascularization because of
comorbidities. They may achieve satisfactory limb salvage rates
at least in the short term. However, in view of the distal and
diffuse nature of the disease in diabetic patients, the procedures
are technically difficult to perform. The distal run off tends to be
poor and hence the results are worse, revascularization is often
not possible and amputation rates are much higher in diabetic
patients with critical limb ischaemia [14].
Outcomes
The results of PCTA with or without stenting are better for
proximal lesions, with reported primary patency rates of 90% at
1 year [10] and 85% at 4 years for iliac angioplasty, and 80% at
1 year for femoral angioplasty. Re-stenosis rates are higher in
diabetic compared with non-diabetic patients after
femoropopliteal PCTA [59] and high lipoprotein(a) levels [59]
predict restenosis. Antiplatelet agents and cilostazol reduce
restenosis rates after PCTA.
Graft occlusion after peripheral revascularization procedures
is higher and limb salvage rates are lower in patients with DM [1].
However, limb salvage rates were similar in diabetic and non-
diabetic patients after distal revascularization in some studies
[60]. Peripheral neuropathy and foot ulceration are associated
with lower limb salvage rates in diabetic patients.
Survival of diabetic patients following a surgical
revascularization procedure is slightly lower than that in non-
diabetic patients, but similar for more proximal procedures [1].
12
Peripheral arterial disease in diabetes • E. B. Jude et al.
However, the outcome after amputation in diabetic patients with
PAD is poorer. The 3-year survival after an amputation is < 50%
and a second amputation is exceedingly common after the first;
survival is lower than in non-diabetic subjects undergoing
successful revascularization [3]. A proposed protocol for the
management of PAD in patients with DM is depicted in Fig. 2.
Summary
Patients with DM are prone to develop PAD. PAD begins
earlier, progresses more rapidly and is more commonly
asymptomatic in DM. Distal arterial involvement of the tibial
and peroneal arteries is the predominant pattern. Lifestyle
modifications are of benefit. Drug therapy is advised in patients
who do not respond to lifestyle modification. Antiplatelet
therapy can retard the onset and progression of PAD and reduce
cardiovascular events in diabetic patients. Therapeutic
angiogenesis represents a promising therapeutic adjunct in the
management of PAD and further research is needed. The results
of revascularization procedures for proximal lesions are similar
to those in non-diabetic patients, but results in distal bypasses
are poor in the long term. Amputation rates after
revascularization are much higher in diabetic than in non-
diabetic patients. Mortality in general and perioperative
mortality are also high in diabetic patients. Early, aggressive
management of the risk factors and timely referral for
revascularization might improve outcome in patients with PAD.
Competing interests
Nothing to declare.
References
1 American Diabetes Association. Peripheral arterial disease in people
with diabetes. Diabetes Care 2003; 26: 3333–3341.
2 Jude EB. Intermittent claudication in the patient with diabetes. Br J
Diabetes Vasc Dis 2004; 4: 238–242.
3 Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial
disease in diabetic and nondiabetic patients: a comparison of
severity and outcome. Diabetes Care 2001; 24: 1433–1437.
4 Kannel WB, McGee DL. Update on some epidemiologic features of
intermittent claudication: the Framingham Study. J Am Geriatr Soc
1985; 33: 13–18.
5 Melton LJ III, Macken KM, Palumbo PJ, Elveback LR. Incidence and
prevalence of clinical peripheral vascular disease in a population-
based cohort of diabetic patients. Diabetes Care 1980; 3: 650–654.
6 Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine
RJ. Peripheral arterial disease in relation to glycaemic level in an
elderly Caucasian population: the Hoorn study. Diabetologia 1995;
38: 86–96.
7 Elhadd T, Robb R, Jung R, Stonebridge P, Belch J. Pilot study of
prevalence of asymptomatic peripheral arterial occlusive disease in
patients with diabetes attending a hospital clinic. Pract Diabetes Int
1999; 16: 163–166.
8 Welborn TA, Knuiman M, McCann V, Stanton K, Constable IJ.
Clinical macrovascular disease in Caucasoid diabetic subjects: lo-
gistic regression analysis of risk variables. Diabetologia 1984; 27:
568–573.
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
 Review article
9 Walters DP, Gatling W, Mullee MA, Hill RD. The prevalence,
detection, and epidemiological correlates of peripheral vascular
disease: a comparison of diabetic and non-diabetic subjects in an
English community. Diabet Med 1992; 9: 710–715.
10 Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD). TASC Working Group. TransAtlantic Inter-Society
Consensus (TASC). J Vasc Surg 2000; 31: S1–S296.
11 Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard
TJ. Glycemia (or, in women, estimated glucose disposal rate) pre-
dict lower extremity arterial disease events in type 1 diabetes.
Metabolism 2002; 51: 248–254.
12 Faglia E, Favales F, Quarantiello A, Calia P, Clelia P, Brambilla G
et al. Angiographic evaluation of peripheral arterial occlusive dis-
ease and its role as a prognostic determinant for major amputation
in diabetic subjects with foot ulcers. Diabetes Care 1998; 21: 625–
630.
13 Malmstedt J, Leander K, Wahlberg E, Karlstrom L, Alfredsson L,
Swedenborg J. Outcome after leg bypass surgery for critical limb
ischemia is poor in patients with diabetes: a population-based co-
hort study. Diabetes Care 2008; 31: 887–892.
14 Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M et al.
Early and five-year amputation and survival rate of diabetic patients
with critical limb ischemia: data of a cohort study of 564 patients.
Eur J Vasc Endovasc Surg 2006; 32: 484–490.
15 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW.
Prevalence and clinical correlates of peripheral arterial disease in the
Framingham Offspring Study. Am Heart J 2002; 143: 961–965.
16 Abbott RD, Brand FN, Kannel WB. Epidemiology of some
peripheral arterial findings in diabetic men and women: experiences
from the Framingham Study. Am J Med 1990; 88: 376–381.
17 Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR.
UKPDS 59: hyperglycemia and other potentially modifiable risk
factors for peripheral vascular disease in type 2 diabetes. Diabetes
Care 2002; 25: 894–899.
18 Zander E, Heinke P, Reindel J, Kohnert KD, Kairies U, Braun J
et al. Peripheral arterial disease in diabetes mellitus type 1
and type 2: are there different risk factors? Vasa 2002; 31: 249–
254.
19 Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-
term follow-up after tight control of blood pressure in type 2 dia-
betes. N Engl J Med 2008; 359: 1565–1576.
20 Laakso M, Pyorala K. Lipid and lipoprotein abnormalities in dia-
betic patients with peripheral vascular disease. Atherosclerosis
1988; 74: 55–63.
21 Katsilambros NL, Tsapogas PC, Arvanitis MP, Tritos NA, Alexiou
ZP, Rigas KL. Risk factors for lower extremity arterial disease in
non-insulin-dependent diabetic persons. Diabet Med 1996; 13:
243–246.
22 James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D.
Lipoprotein (a) and vascular disease in diabetic patients. Diabeto-
logia 1995; 38: 711–714.
23 O’Neal DN, Lewicki J, Ansari MZ, Matthews PG, Best JD. Lipid
levels and peripheral vascular disease in diabetic and non-diabetic
subjects. Atherosclerosis 1998; 136: 1–8.
24 Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Ze-
nari L et al. HOMA-estimated insulin resistance is an independent
predictor of cardiovascular disease in type 2 diabetic subjects:
prospective data from the Verona Diabetes Complications Study.
Diabetes Care 2002; 25: 1135–1141.
25 Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine
and atherosclerotic peripheral vascular disease. Ann Vasc Surg
1997; 11: 217–223.
26 Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski WE. Coag-
ulation in diabetic and non-diabetic claudicants. Int Angiol 2002;
21: 128–133.
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14
DIABETICMedicine
27 Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Cir-
culating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-
selectin in the prediction of cardiovascular disease in diabetes
mellitus. Eur J Intern Med 2002; 13: 185–189.
28 Marso SP, Hiatt WR. Peripheral arterial disease in patients with
diabetes. J Am Coll Cardiol 2006; 47: 921–929.
29 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002;
287: 2570–2581.
30 Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH
et al. Diabetes mellitus enhances vascular matrix metalloproteinase
activity: role of oxidative stress. Circ Res 2001; 88: 1291–1298.
31 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+)
homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol
2001; 280: H1480–H1489.
32 Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet
dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476–
1485.
33 Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes
Complications 2001; 15: 44–54.
34 Hirsch AT, Hiatt WR. PAD awareness, risk, and treatment: new
resources for survival—the USA PARTNERS program. Vasc Med
2001; 6: 9–12.
35 Dyet JF, Nicholson AA, Ettles DF. Vascular imaging and inter-
vention in peripheral arteries in the diabetic patient. Diabetes Me-
tab Res Rev 2000; 16 (Suppl. 1): S16–S22.
36 Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-
onset diabetic foot ulcers stratified by etiology. Diabetes Care 2003;
26: 491–494.
37 Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C
et al. Peripheral artery disease, diabetes, and reduced lower
extremity functioning. Diabetes Care 2002; 25: 113–120.
38 Carser DG. Do we need to reappraise our method of interpreting
the ankle brachial pressure index? J Wound Care 2001; 10: 59–
62.
39 Costacou T, Huskey ND, Edmundowicz D, Stolk R, Orchard TJ.
Lower-extremity arterial calcification as a correlate of coronary
artery calcification. Metabolism 2006; 55: 1689–1696.
40 Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, Criqui MH.
The association between elevated ankle systolic pressures and
peripheral occlusive arterial disease in diabetic and nondiabetic
subjects. J Vasc Surg 2008; 48: 1197–1203.
41 Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF et al. The
effects of exercise training on walking function and perception of
health status in elderly patients with peripheral arterial occlusive
disease. J Intern Med 2002; 252: 448–455.
42 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year
follow-up of intensive glucose control in type 2 diabetes. N Engl J
Med 2008; 359: 1577–1589.
43 Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L.
Impact of peripheral arterial disease in patients with diabe-
tes—results from PROactive (PROactive 11). Atherosclerosis 2009;
202: 272–281.
44 Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG,
Thorgeirsson G. Cholesterol lowering with simvastatin improves
prognosis of diabetic patients with coronary heart disease. A sub-
group analysis of the Scandinavian Simvastatin Survival Study (4S).
Diabetes Care 1997; 20: 614–620.
45 Heart Protection Study Collaborative Group. MRC ⁄ BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial. Lancet
2002; 360: 7–22.
46 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA,
Neil HA, Livingstone SJ et al. Primary prevention of
cardiovascular disease with atorvastatin in type 2 diabetes in the
13
DIABETICMedicine
Collaborative Atorvastatin Diabetes Study (CARDS): multicen-
tre randomised placebo-controlled trial. Lancet 2004; 364: 685–
696.
47 Heart Outcomes Prevention Evaluation Study Investigators. Effects
of ramipril on cardiovascular and microvascular outcomes in people
with diabetes mellitus: results of the HOPE study and MICRO-
HOPE substudy. Heart Outcomes Prevention Evaluation Study
Investigators. Lancet 2000; 355: 253–259.
48 Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR.
Intensive blood pressure control reduces the risk of cardiovascular
events in patients with peripheral arterial disease and type 2 dia-
betes. Circulation 2003; 107: 753–756.
49 Radack K, Deck C. Beta-adrenergic blocker therapy does not
worsen intermittent claudication in subjects with peripheral arterial
disease. A meta-analysis of randomized controlled trials. Arch In-
tern Med 1991; 151: 1769–1776.
50 Antiplatelet Trialists’ Collaboration. Collaborative overview of
randomised trials of antiplatelet therapy—I: prevention of death,
myocardial infarction, and stroke by prolonged antiplatelet therapy
in various categories of patients. Antiplatelet Trialists’ Collabora-
tion. BMJ 1994; 308: 81–106.
51 Antiplatelet Trialists’ Collaboration. Collaborative overview of
randomised trials of antiplatelet therapy—II: maintenance of vas-
cular graft or arterial patency by antiplatelet therapy. Antiplatelet
Trialists’ Collaboration. BMJ 1994; 308: 159–168.
52 Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of
platelet function delays progression of peripheral occlusive arterial
disease. A prospective double-blind arteriographically controlled
trial. Lancet 1985; 1: 415–419.
14
Peripheral arterial disease in diabetes • E. B. Jude et al.
53 CAPRIE Steering Committee. A randomised, blinded, trial of
clopidogrel versus aspirin in patients at risk of ischaemic events
(CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329–
1339.
54 Chapman TM, Goa KL. Cilostazol: a review of its use in inter-
mittent claudication. Am J Cardiovasc Drugs 2003; 3: 117–138.
55 Rendell M, Cariski AT, Hittel N, Zhang P. Cilostazol treatment of
claudication in diabetic patients. Curr Med Res Opin 2002; 18:
479–487.
56 Cozzolino D, Coppola L, Masi S, Salvatore T, Sasso FC, De Lucia D
et al. Short- and long-term treatments with iloprost in diabetic
patients with peripheral vascular disease: effects on the cardiovas-
cular risk factor plasminogen activator inhibitor type-1. Eur J Clin
Pharmacol 1999; 55: 491–497.
57 Papanas N, Maltezos E. Advances in treating the ischaemic diabetic
foot. Curr Vasc Pharmacol 2008; 6: 23–28.
58 Yang XF, Wu YX, Wang HM, Xu YF, Lu X, Zhang YB et al.
[Autologous peripheral blood stem cells transplantation in treat-
ment of 62 cases of lower extremity ischemic disorder]. Zhonghua
Nei Ke Za Zhi 2005; 44: 95–98.
59 Maca TH, Ahmadi R, Derfler K, Ehringer H, Gschwandtner ME,
Horl W et al. Influence of lipoprotein(a) on restenosis after fem-
oropopliteal percutaneous transluminal angioplasty in Type 2 dia-
betic patients. Diabet Med 2002; 19: 300–306.
60 Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG,
Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on
long-term outcome. Ann Vasc Surg 2000; 14: 640–647.
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 4–14